Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 5, 1999, Pages 510-521

  Becker, Erika ^b   Richardson, Des R ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033230124     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90173-7     Document Type: Article

References (52)

1. 1. Olivieri NF, Brittenham GM. Iron - chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
2. 2. Richardson DR, Ponka P. The development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am J Hematol 1998;58:299-305.
3. 3. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-23.
4. 4. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979;97:317-21.
5. 5. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 1979;586:278-97.
6. 6. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 1979;43:443-9.
7. 7. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S. Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 1981;98:99-108.
8. 8. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs. Potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 1998;131:306-15.
9. 9. Richardson DR, Hefter GT, May PM, Webb J, Baker E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Metals 1989;2:161-7.
10. 10. Vitolo LMW, Hefter GT, Clare BW, Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg Chim Acta 1990;170:171-6.
11. 11. Morgan EH. Chelator-mediated iron efflux from reticulocytes. Biochim Biophys Acta 1983;733:39-50.
12. 12. Ponka P, Wilczynska A, Schulman HM. Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor of haem synthesis. Biochim Biophys Acta 1982;720:96-102.
13. 13. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 1997;276:1709-12.
14. 14. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in the mitochondrion. FEBS Lett 1997;411:373-7.
15. 15. Rötig A, de-Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet 1997;17:215-7.
16. 16. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 1992;15:492-501.
17. 17. Richardson DR, Tran E, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents. Blood 1995;86:4295-306.
18. 18. Richardson DR, Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997;89:3025-38.
19. 19. Bláha K, Cikrt M, Nerudová J, Fornusková H. Ponka P. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood 1998;91:4368-72.
20. 20. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781-92.
21. 21. Richardson DR. Potential of iron chelators as effective anti-proliferative agents. Can J Physiol Pharmacol 1997;75:1164-80.
22. 22. Becton DL, Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 1988;48: 7189-92.
23. 23. Blatt J, Taylor SR, Stitely S. Mechanism of antineuroblastoma activity of deferoxamine in vitro. J Lab Clin Med 1988; 112:433-6.
24. 24. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990;50:4929-30.
25. 25. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, et al. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): a new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 1992;15:319-22.
26. 26. Cory JG, Cory AH, Rappa G, Lorico A, Liu MC, Lin TS, Sartorelli AC. Structure-function relationships for a new series of pyridine-2-carboxaldehyde thiosemicarbazones on ribonucleotide reductase activity and tumour cell growth in culture and in vivo. Adv Enzyme Regul 1995;35:55-68.
27. 27. Liu M-C, Lin T-S, Sartorelli AC. Chemical and biological properties of cytotoxic α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 1995;32:1-35.
28. 28. Johnson DK, Murphy TB, Rose NJ, Goodwin WH, Pickart L. Cytotoxic chelators and chelates I. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg Chim Acta 1982;67:159-62.
29. 29. Richardson DR, Baker E. The uptake of iron and transferrin by the human melanoma cell. Biochim Biophys Acta 1990; 1053:1-12.
30. 30. Richardson DR, Ponka P. The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med 1994;124:660-71.
31. 31. Baker E, Baker SM, Morgan EH. Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture. Biochim Biophys Acta 1998;1380:21-30.
32. 32. Leibold EA, Munro HN. Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy-and light-subumit mRNAs. Proc Natl Acad Sci USA 1988;85:2171-5.
33. 33. Müllner EW, Neupert B, Kühn LC. A specific mRNA binding factor regulates the iron-dependent stability of the cytoplasmic transferrin receptor mRNA. Cell 1989;58:373-82.
34. 34. Konarska MM, Sharp PA. Electrophoretic separation of complexes involved in the splicing of precursors to mRNAs. Cell 1986;46:845-55.
35. 35. Mahmoudi M, Lin VK. Comparison of two different hybridization systems in northern transfer analysis. Biotechniques 1989;7:331-2.
36. 36. Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996;93:8175-82.
37. 37. Chitambar CR, Wereley JP. Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis. Cancer Res 1995;55:4361-6.
38. 38. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
39. 39. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAFI, a potent mediator of p53 tumor suppression. Cell 1993;75:817-25.
40. 40. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
41. 41. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
42. 42. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995;92:8493-7.
43. 43. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle check point pathway utilizing p53 and gadd45 is defective in ataxia telangiectasia. Cell 1992;71:587-97.
44. 44. Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemic cell lines. Cancer Res 1992;52:4591-9.
45. 45. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, et al. Neuroblastoma sensitivity to growth inhibition by deferoxamine: evidence for a block in the G1 phase of the cell cycle. Cancer Res 1993;53:3968-75.
46. 46. Domiano P, Musatti A, Nardelli M, Pelizzi C. Crystal structure and chemical properties of bis(N-picolinylidene-N'-salicyloylhydrazinato)nickle(II). J Chem Soc Dalton Trans 1975;295-300.
47. 10-metal complexes of pyridine-2-carbaldehyde salicyloylhydrazone and x-ray structure of the zinc derivative. Polyhedron 1984;3:281-6.
48. 48. Bacchi A, Carcelli M, Costa M, Pelgatti P, Pelizzi C, Pelizzi G. Versatile ligand behaviour of phenyl 2-pyridyl ketone benzoylhydrazone in palladium(II) complexes. J Chem Soc Dalton Trans 1996;4239-44.
49. 49. Porter JB, Gyparaki M, Burke LC, Huehns ER, Sarpong P, Saez V, et al. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 1988;72:1497-503.
50. 50. Ponka P, Richardson DR, Edward JT, Chubb FL. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to remove iron from reticulocytes in vitro. Can J Physiol Pharmacol 1994;72:659-66.
51. 51. Thelander L, Reichard P. The reduction of ribonucleotides. Annu Rev Biochem 1979;48:133-58.
52. 52. Richardson DR, Bernhardt PV. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with antitumour activity. J Biol Inorg Chem 1999;4:266-73.